OTC : NPPNY
$0 (0.0%)
OTC
Yuichiro Wakatsuki Wee Siew Kim
Medical - Pharmaceuticals
Healthcare
NPPNY
2309
JP
USD
0.01
4.35
3.12
1.82
0.28
$181.07B
1.41
0.83
9.95
89.96
$116.64
$31.51B
17.40%
21.35%
10.94%
8.58%
8.11
-0.93
-0.93
4/5
0 Analysts
%
5.57
5/9
$142.88B
$342.87B
$49.09B
$34.93B
$167.2B
0.98
3.87
4.35
10.94%
8.83%
12.33%
10.05%
$6555.09
260 days
| Name | Title |
|---|---|
| Mitsuharu Koizumi | Dir. of HR, Gen. Aff., Risk Man., Compliance, Sustain. & Dig.Tran. and Director |
| Takanori Edamitsu | MD of Business Management & Director |
| Kazuyuki Yamate | Corporate Officer & Head of Digital Transformation Div. |
| Hitomi Kimura | GM of Resource Procurement, Production and Assurance Div. & Director |
| Yoko Nakanishi | Corporate Officer & Department Manager of Human Resources Dept. |
| Hitoshi Ishizawa | GM of Functional Food, Head of Functional Food Division & Director |
| Takashi Takaya | GM of Personnel, General Affairs, Risk Mgmt, Compliance & Digital Trans and Director |
| Toru Nakai | President & Representative Director |
| Manabu Beppu | Corporate Officer and Head of R & D Planning and Administration Div. |
| Masaya Toda | Head of Licensing & Alliance Division and Corporate Officer |
| Hideyuki Fujii | Accounting & Finance Department Manager |
| Kazuyuki Iwata | GM of Sales and Marketing, Head of Sales & Marketing Division and Director |
| Hayato Wada | Corporate Officer & Department Manager of Kansai Business Office |
No votes yet today — be the first to share your view!
About Nippon Shinyaku Co., Ltd. (OTC:NPPNY) Stock
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan. ...
Frequently Asked Questions
What is the current Nippon Shinyaku Co., Ltd. (NPPNY) stock price?
Nippon Shinyaku Co., Ltd.(OTC:NPPNY) stock price is $6.11 in the last trading session. During the trading session, NPPNY stock reached the peak price of $15.21 while $5.0275 was the lowest point it dropped to. The percentage change in NPPNY stock occurred in the recent session was 0.0% while the dollar amount for the price change in NPPNY stock was $0.
NPPNY's industry and sector of operation?
The OTC listed NPPNY is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
Who are the executives of NPPNY?
Mitsuharu Koizumi
| Dir. of HR, Gen. Aff., Risk Man., Compliance, Sustain. & Dig.Tran. and Director
Takanori Edamitsu
| MD of Business Management & Director
Kazuyuki Yamate
| Corporate Officer & Head of Digital Transformation Div.
Hitomi Kimura
| GM of Resource Procurement, Production and Assurance Div. & Director
Yoko Nakanishi
| Corporate Officer & Department Manager of Human Resources Dept.
How many employees does NPPNY have?
Number of NPPNY employees currently stands at 2309. NPPNY operates from 14, Nishinosho-Monguchi-cho, Kyoto, KY 601-8550, JP.
Link for NPPNY official website?
Official Website of NPPNY is: https://www.nippon-shinyaku.co.jp
How do I contact NPPNY?
NPPNY could be contacted at phone #81 7 5321 1111 and can also be accessed through its website. NPPNY operates from 14, Nishinosho-Monguchi-cho, Kyoto, KY 601-8550, JP.
How many shares of NPPNY are traded daily?
The average number of NPPNY shares traded daily for last 3 months was 59.
What is the market cap of NPPNY currently?
The market value of NPPNY currently stands at $1.65B with its latest stock price at $6.11